Plain-English translation of NCT02865850 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Kidney disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tested , an oral medication taken by mouth, compared to a standard injectable treatment called . The study examined whether could safely and effectively help treat anemia (low red blood cell counts) in people who had recently started dialysis because of severe kidney disease. Anemia is a common problem for dialysis patients and can cause fatigue and other health complications.
People with kidney failure who need dialysis often develop anemia because their kidneys no longer produce enough of a natural hormone that helps make red blood cells. This medication was being tested as a potentially easier-to-take alternative (a pill instead of an injection) to help their bodies make healthy red blood cells again.
Participants were randomly assigned to take either as an oral medication or receive as an injection — the standard treatment. Throughout the trial, participants visited the clinic regularly for blood tests to check their hemoglobin levels and to monitor their overall health and safety. The trial followed participants over a period of time to see how well each treatment worked and whether it was safe.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
United States